BIOMAT Database Logo BIOMAT Database Logo

Bortezomib for refractory antibody-mediated cardiac allograft rejection. 2009

Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Department of Medicine, University of Minnesota, USA.

This experience demonstrates that a bortezomib-based regimen provided effective therapy for late, refractory AMR in an adult heart transplant recipient and was well tolerated. This remarkably positive experience despite the refractory nature of the AMR episode argues strongly for continued evaluation of bortezomib use in this patient population.

UI MeSH Term Description Entries
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D001897 Boronic Acids Inorganic or organic compounds that contain the basic structure RB(OH)2. Boronic Acid,Acid, Boronic,Acids, Boronic
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069286 Bortezomib A pyrazine and boronic acid derivative that functions as a reversible PROTEASOME INHIBITOR. It is used as an ANTINEOPLASTIC AGENT in the treatment of MULTIPLE MYELOMA and MANTLE CELL LYMPHOMA. LDP-341,PS 341,PS-341,Velcade,341, PS,LDP 341,LDP341,PS341

Related Publications

Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report.
June 2015, Progress in transplantation (Aliso Viejo, Calif.),
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection.
January 2010, Clinical transplants,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
January 2009, Clinical transplants,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Treatment of refractory cardiac allograft rejection with OKT3 monoclonal antibody.
February 1987, The American journal of medicine,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
January 2010, Clinical transplants,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Late Cardiac Allograft Failure, Cardiac Allograft Vasculopathy, and Antibody-Mediated Rejection: Untangling Some Knots?
January 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Antibody-mediated organ-allograft rejection.
October 2005, Nature reviews. Immunology,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Proteasome inhibition for antibody-mediated allograft rejection.
July 2012, Seminars in hematology,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection-a pilot study.
December 2018, HLA,
Peter M Eckman, and Marit Thorsgard, and David Maurer, and Youngki Kim, and Rita R Alloway, and E Steve Woodle
Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
March 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Copied contents to your clipboard!